Is Compounded Tirzepatide Still Legal in 2025–2026?

# [H1] Is Compounded Tirzepatide Still Legal? What the Latest FDA Actions Actually Mean

If you've been following GLP-1 research or weight loss pharmacology, you've likely seen the headlines: the FDA is cracking down on compounded tirzepatide — but the full picture is more nuanced than a simple yes or no. So, *is compounded tirzepatide still legal?* The answer depends on who is compounding it, under what authority, and when you're reading this. Here's a clear-eyed breakdown of where things actually stand.

## [H2] The Regulatory Timeline: How We Got Here

To understand the current legal status, you need to understand the mechanism that made compounded tirzepatide possible in the first place.

Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to produce copies of FDA-approved drugs — but only when those drugs are on the FDA's official drug shortage list. Tirzepatide (brand name Mounjaro for diabetes, Zepbound for weight loss) landed on that shortage list in 2022 as demand for GLP-1 receptor agonists exploded following clinical data from the SURMOUNT-1 trial, published in the *New England Journal of Medicine* in 2022, which showed participants losing up to 20.9% of body weight over 72 weeks (Jastreboff et al., NEJM, 2022).

That shortage created a legal window. Hundreds of compounding pharmacies stepped in to fill the gap — legally, at the time.

In late 2024 and into 2025, the FDA determined that the tirzepatide shortage had been resolved. Once a drug is removed from the shortage list, the legal basis for widespread compounding collapses. The FDA subsequently moved to enforce this, issuing 30 warning letters to compounders still producing tirzepatide and semaglutide outside of shortage-authorized frameworks, according to reporting by *Fierce Pharma*. More sweeping action followed, with *Pharmacy Times* reporting that the FDA is now moving to permanently close the door on compounded GLP-1s as a category — not just as a temporary enforcement posture.

## [H2] What "Still Legal" Actually Means Right Now

The short answer: mass-produced compounded tirzepatide from 503B outsourcing facilities is no longer on solid legal ground as of 2025. However, the picture is slightly different for 503A pharmacies, which can still technically compound tirzepatide for an individual patient under a specific prescription where a documented clinical need exists — such as a required dosage strength not commercially available.

Everyday Health* reported directly on this distinction, noting that the FDA's ban is most clearly directed at large-scale compounders and telehealth platforms dispensing compounded GLP-1s at volume without individualized medical justification.

For 2026, the regulatory environment is expected to tighten further. Platforms that built business models around compounded tirzepatide subscriptions are already pivoting or shutting down relevant offerings. One consumer-facing analysis published via *Newswire* highlighted that GLP-1 program pricing structures and enrollment terms are shifting materially in response to the compounding deadline.

## [H2] What the Research Still Shows

None of this regulatory activity changes the underlying clinical data — and that data is significant. The SURMOUNT-1 trial demonstrated tirzepatide's dual GIP/GLP-1 agonism produced weight loss outcomes that outperformed earlier GLP-1 monotherapies. A 2023 follow-up trial, SURMOUNT-4, confirmed that discontinuing tirzepatide led to substantial weight regain, underscoring its role as an ongoing research compound rather than a short-term intervention (Aronne et al., NEJM, 2024).

Mechanistically, tirzepatide works by activating both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously — a dual-agonist action that improves insulin sensitivity, slows gastric emptying, and reduces caloric intake through central appetite suppression. This dual mechanism is why tirzepatide produces meaningfully greater weight reduction than GLP-1 single-agonists like semaglutide in head-to-head comparisons.

## [H2] Key Takeaways

• Compounded tirzepatide's legal status shifted when the FDA declared the shortage resolved — large-scale compounding is no longer authorized under shortage exemptions
• 503A pharmacies may still compound for individual patients with documented clinical need, but this is narrow and case-by-case
• The FDA issued 30+ warning letters in 2025 and is pursuing permanent restrictions on compounded GLP-1s as a category
• The underlying clinical data for tirzepatide (SURMOUNT-1, SURMOUNT-4) remains robust and continues to drive research interest
• 2026 will likely see further enforcement, making it critical to distinguish between research-grade supply chains and commercial compounding